Literature DB >> 2652320

In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence.

S Binet1, A Fellous, H Lataste, A Krikorian, J P Couzinier, V Meininger.   

Abstract

Preliminary clinical studies demonstrated that 5' nor-anhydro-vinblastine, Navelbine (NVB) has a broader antitumor activity and fewer neurotoxic effects than vinblastine or vincristine. The tectal plate anlage of mouse embryos at the earliest stages of neuronal differentiation were used to analyze and compare the effect of NVB, vincristine and vinblastine on axonal and mitotic microtubules after culture of post-implantation embryos in a medium containing the agent. All drugs are active on mitotic microtubules at the same concentration (0.1 mumol/L), inducing a depolymerization of microtubules and a blockade of cells at metaphase. At higher concentrations. NVB is the only one of the three drugs that induces a blockade of the cells at prophase. A depolymerization of axonal microtubules occurs at higher concentrations with NVB than with the two other vinca alkaloids. These results demonstrate that NVB is as active on mitotic microtubules and less active on axonal microtubules than vincristine and vinblastine. These findings can be related to the potent antitumor effect of the drug with minor neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2652320

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  21 in total

1.  A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study.

Authors:  C S Higano; J J Crowley; R V Veith; R B Livingston
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.

Authors:  Kaisa Erjala; Misa Raitanen; Jarmo Kulmala; Reidar Grénman
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-05       Impact factor: 4.553

3.  Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines.

Authors:  A Photiou; M N Sheikh; D Bafaloukos; S Retsas
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

4.  Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study.

Authors:  M Terenziani; R Demicheli; C Brambilla; L Ferrari; A Moliterni; M Zambetti; A Caraceni; C Martini; G Bonadonna
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 5.  Promising new agents in the treatment of non-small cell lung cancer.

Authors:  M J Edelman; D R Gandara
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 6.  New oral chemotherapeutic agents for lung cancer.

Authors:  E M Bengtson; J R Rigas
Journal:  Drugs       Date:  1999       Impact factor: 9.546

7.  Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients.

Authors:  T Schilling; H H Fiebig; S Kerpel-Fronius; B Winterhalter; P Variol; P Tresca; B Heinrich; A R Hanauske
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 8.  The current and future place of vinorelbine in cancer therapy.

Authors:  E Cvitkovic; J Izzo
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 9.  Vinorelbine. A review of its antitumour activity in lung cancer.

Authors:  J B Sørensen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

10.  Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience.

Authors:  Maura Massimino; Filippo Spreafico; Veronica Biassoni; Fabio Simonetti; Daria Riva; Giovanna Trecate; Sergio Giombini; Geraldina Poggi; Emilia Pecori; Emanuele Pignoli; Michela Casanova; Andrea Ferrari; Cristina Meazza; Roberto Luksch; Monica Terenziani; Graziella Cefalo; Marta Podda; Daniela Polastri; Carlo A Clerici; Franca Fossati-Bellani; Lorenza Gandola
Journal:  J Neurooncol       Date:  2008-01-24       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.